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Summary 
 
Platelets are a critical cell for prevention of bleeding. Part of the response to the 
formation of the thrombus is the activation of the actin cytoskeleton, with an inability to 
effectively activate the cytoskeleton linked to thrombus formation defects and instability.  
The control of this process is linked to activation of the Rho GTPases, Cdc42, Rac1 and 
RhoA, although additional small GTPases such as Rif and Rap have been shown to play 
roles in platelet function. 
 
Here we will describe the methodology to accurately understand how Rho GTPases are 
activated in platelets. Due to the technical limitations of working with platelets, such as 
their lack of ability to be transfected, the majority of work has been carried out either 
using inhibitors of Rho GTPases or within knock out mouse models. Studies can be 
conducted both in suspension samples and also in spread platelets. In suspension the 
platelets will undergo a shape change response, but will not be able to spread. In spread 
platelets it is possible to examine the effects of the matrix environment, such as 
concentration, type and stiffness on Rho GTPase function within platelet activation and 
platelet spreading.  
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1. Introduction 
 
Platelets are a blood cell critical to maintaining hemostasis. Too few platelets leads to a 
bleeding phenotype, whilst too many can lead to excessive thrombus formation and therefore 
heart attack or stroke. During thrombus formation the platelets undergo a coordinated 
activation process initiated by platelet agonists. This coordinated approach allows for the 
platelets to form a strong and effective thrombus that can resist the shear stress present 
within the blood vessel.  A key part of this response is that the platelet can effectively 
rearrange its actin cytoskeleton and the production of fully or partially spread platelets, 
dependent on where they are in the thrombus.  
 
Platelet spreading is a coordinated rearrangement of the platelet shape in response to the 
presence of an extracellular matrix protein. This spreading process is controlled by the 
activity of the Rho GTPases (1). There are over 20 small GTPases among mammalian cells, 
with differing expression patterns according to cell type (reviewed in ref. (2)). The most well-
known Rho GTPases, Cdc42, Rac, and RhoA, have been extensively researched and have 
been linked to formation of filopodia, lamellipodia and stress fibers respectively (1, 2). In 
platelets the role of Cdc42 is unclear. One study showed that platelets lacking Cdc42 do not 
form filopodia on fibrinogen and collagen related peptide (CRP), whilst a second study 
showed no effect on fibrinogen, but an inhibition of filopodia formation on von Willebrand 
factor (3, 4).  Furthermore, Rif has also been proposed as a filopodia initiator, but Cdc42 may 
be able to compensate for its loss (5).  However, Rac1 has been conclusively shown via 
chemical inhibition and knock out studies to control lamellipod formation in platelets (6). RhoA 
has been shown to control platelet shape change and stress fibre formation (7-9). In addition 
to filopodia, lamellipodia and stress fibers, the platelet also forms the actin nodule (10). This 
actin structure is thought to be similar to the podosome, as it is a circular actin structure 
dependent on the Arp2/3 complex and tyrosine phosphorylation, and has a ring of vinculin 
and integrins (11). The actin nodule is a dynamic structure that is thought to play a role in 
resistance of shear stress.  Interestingly, the actin nodule is thought to be linked to filopodia 
and lamellipodia formation, as it disappears when stress fibers are formed.   
In addition to the effects on platelet spreading, inhibition of either actin nodules, lamellipodia, 
or stress fiber formation has been shown to lead either to reduction of thrombus formation, 
and/or thrombus instability at arterial rates of shear (8, 11, 12). Furthermore, a sustained 
cytoskeletal response is required, as post perfusion of Rac inhibitors or agents that lead to 
RhoA inhibition causes thrombus instability (12, 13).   
 
The platelet spreading process can be followed in vitro. Initially, matrix proteins are attached 
to a glass coverslip. A number of platelet matrix proteins have been used including Horm 
collagen (a mixture of collagen I and III), fibrinogen, fibronectin, fibrin, von Willebrand factor 
(with or without ristocetin or botrocetin), laminin, the collagen-mimetic peptide GFOGER, 
CRP, oxidized low density lipoprotein (oxLDL), thrombin, and thrombospondin-1 (10, 14-20). 
The coverslips are then blocked with bovine serum albumin (BSA) before addition of the 
platelets. The platelets are spread for a designated time before fixation, and if required 
completion of immunofluorescence or proximity ligation. The coverslips are then mounted 
and imaged using differential interference contrast (DIC), conventional fluorescence, confocal 
or superresolution microscopy.  Analysis of the images, can consist of analysis of surface 
area, numbers adhered, number of platelets with filopodia, proportion of cells with stress 
fibers or actin nodules, number of actin nodules per platelet, or the size of actin nodules. 
However, the extent of spreading can depend not only on the type of matrix protein but also 
its concentration, stiffness, and if it is combined with multiple other matrix proteins (16, 21, 
22).  
 
Alongside analysis of fixed platelet samples, real time microscopy can also be conducted. 
This allows for dynamic understanding of the spreading process. Usually this is completed 
using DIC microscopy. However, with the production of Life-act platelets it is possible to 
follow the actin cytoskeleton in real time during the spreading process using fluorescence 
microscopy (11).   
 
Although this assay allows for a global understanding of platelet spreading, it can also be 
used to investigate specific proteins, or for understanding cell signaling within the spreading 
process. In these cases, either knock out platelets or chemical inhibition of proteins can be 
used to understand a particular protein’s role within spreading. These inhibitors can either be 
preincubated with platelets prior to spreading on matrix proteins, or alternatively platelets can 
be allowed to spread before the addition of inhibitors to fully activated and spread platelets. In 
addition to imaging, spread platelets can be lysed and the samples analyzed by Western blot. 
This then allows changes in the phosphorylation status of, for example, RhoA to be 
monitored with phosphor-specific antibodies, and changes in the levels of activated RhoA can 
be monitored using a classical activation (or pull-down) assay based on a fusion protein of 
glutathione-S-transferase (GST) and the Rho GTPase binding domain of effector molecules 
like Rhotekin.  
 
2. Materials 
 
2.1 Platelet Isolation 
 
1. Acid Citrate Dextrose (ACD): 113.8 mM glucose, 29.9 mM trisodium citrate, 72.6 mM 
NaCl and 2.9 mM citric acid. Adjust pH to 6.4. 
2. 0.3 M citric acid.  
3. Modified Tyrode’s buffer: 134 mM NaCl, 20 mM HEPES, 0.34 mM NaH2PO4, 12 mM 
NaHCO3, 2 mM KCl, 1 mM MgCl2 and 5.6 mM glucose. Adjust pH to 7.3. 
4. Wash Buffer: 36 mM citric acid, 10 mM ethylendiaminotetracetic acid (EDTA), 5 mM 
glucose, 5 mM KCl and 90 mM NaCl. Adjust pH to 6.5. 
5. Bijou tubes. 
6. Hypodermic eccentric luer Syringes (1-50-mL)  
7. For human blood withdrawal use Vacutainer safety lok 21G butterfly needles. 
8. For murine blood withdrawal use 25G needles 
9. Single use tourniquet, sterile cotton wool, isopropyl wipes, spot plasters and 
disinfectant wipes. 
10. Swingout centrifuge. 
11. Beckman Coulter counter (ZTM Series Coulter – Cell and Particle Counter) or 
hemocytometer. 
 
2.2 Platelet Spreading 
 
1. Glass coverslips (ø 12 mm) and glass slides. 
2. 6-well and 24-well plates (glass bottomed for real-time spreading) 
3. Phosphate Buffered Saline (PBS), commercially available from various sources. 
4. Matrix proteins (final concentrations): 
a. 3-100 µg/mL fibrinogen (Enzyme Research) prepared fresh in PBS. 
b. 100 µg/mL Horm collagen (Takeda) prepared fresh from 1 mg/mL commercial 
stock in collagen diluent (provided).   
c. 100 µg/mL fibronectin (Sigma) frozen aliquots prepared in PBS 
d. 10-100 µg/mL oxLDL (own source) prepared fresh in PBS (see Note 1). 
e. 10-100 µg/mL native LDL (own source) prepared fresh in PBS (see Note 1). 
f. 10-100 µg/mL laminin (Sigma) frozen aliquots prepared in PBS. 
5. Platelet agonists (final concentrations): 
a. 0.1 U/mL thrombin diluted in PBS from 10 U/mL stock (see Note 2). 
b. 100 µg/mL Horm collagen (Takeda) prepared fresh from 1 mg/mL commercial 
stock in collagen diluent (provided). 
6. Platelet inhibitors (final concentrations): 
a. 10-100 nM prostacyclin (Cayman Chemicals) diluted in PBS; prepare a 2 mM 
stock solution in methanol and store aliquots at -20°C (see Note 3). 
b. 10 nM-1 µM S-nitrosoglutathione (GSNO) (nitric oxide donor) diluted in PBS. 
c. 2 U/mL apyrase diluted in PBS. 
d. 10 µM indomethacin diluted in PBS from stock; prepare a 10 mM stock 
solution in dimethylsulfoxide (DMSO) (see Note 4). 
7. Incubator (37°C). 
8. PBS-BSA: BSA that is depleted of fibrinogen, fibronectin and von Willebrand factor 
(Sigma) is dissolved in PBS to 5 mg/mL in a conical tube. The BSA is then denatured 
by placing the conical tube in boiling water for 10 min, before being cooled on ice to 
room temperature, at which point it is filtered with a 0.45-µm filter. After filtration the 
BSA can be stored frozen and the relevant amount defrosted for each experiment 
(see Note 5). 
9. Rho GTPase inhibitors (final concentrations): 
a. 50 µM NSC23766 prepared in water and frozen as 50 mM stock. 
b. 10 µM EHT1864 prepared in water and frozen as 10 mM stock. 
c. 10 µM Y27632 prepared in water and frozen as 10 mM stock. 
d. 10 µM RhosinA prepared in DMSO and frozen as 10 mM stock. 
10. Fixing solution: 4% paraformaldehyde, diluted in PBS from commercial 16% solution 
(Fisher). 
11. Permeabilizing solution: 0.1% (v/v) Triton-X-100 in PBS. 
12. Fluorescein isothiocyanate (FITC)-labeled phalloidin (Sigma P5282) or 
tetramethylrhodamine isothiocyanate (TRITC)-labeled phalloidin (Sigma P1951): 
Dissolve to 0.1 mg/mL in methanol to obtain a 100 µg/mL stock solution. Store at -
20C protected from light (see Note 6). 
13. Primary antibodies: Arp2/3 complex (p34 Arp2 subunit, Millipore), vinculin (clone 
hVIN-1, V9131 Sigma) and monoclonal anti-phosphotyrosine (clone 4G10, 05-1050 
Millipore) can be used to label actin nodules. Primary antibodies specific for various 
other actin cytoskeleton components are available commercially or from researchers, 
as per the experimental requirements. 
14. Secondary antibodies: choose from a variety of Alexa-coupled secondary antibodies 
(Invitrogen) depending on the host species of the primary antibody and the 
combination of fluorochromes required in the case of double staining. 
15. Prolong Diamond antifade mounting medium (Thermo Scientific) or equivalent. 
16. Conventional fluorescence microscope or confocal microscope equipped with 63× or 
100× oil immersion lenses. 
17. Inverted fluorescence microscope equipped with 63× or 100× oil immersion lenses 
and differential interference contrast (DIC) setup. 
18. Image J: Available at https://imagej.nih.gov/ij/download.html. 
2.3. Westerns Blot and RhoA/Rac1 Activation Assay 
 
1. 6-well plates or 10-cm plastic dishes. 
2. PBS (see Subheading 2.2 item 3) 
3. PBS-BSA (see Subheading 2.2 item 8)  
4. Matrix proteins (see Subheading 2.2 item 4) 
5. Cell scrapers 
6. Lysis buffer general – signalling (phosphorylation status of RhoA/Rac) (300 mM NaCl, 
20 mM Tris, 2 mM EDTA, 2 mM EGTA, 2% NP-40). 
7. Protein concentration determination kit (Cytoskeleton). 
8. 6× Laemmli buffer: 30% sodium dodecylsulfate (SDS), 4.7 mL of glycerol, 1.2 mL of 
0.5 M Tris-HCl pH 6.8, 6 mg of bromophenol blue and 0.93 g of dithiothreitol (DTT) in 
10 mL of distilled water. 
9. Platelet agonists (see Subheading 2.2 item 5) 
10. Platelet inhibitors (see Subheading 2.2 item 6) 
11. Primary antibodies:  
a. Phospho RhoASer188 (Santa Cruz) 
b. Phospho Rac1Ser71 (Cell Signalling Technology) 
c. RhoA (New England Biolabs). 
d. Rac1 (New England Biolabs). 
e. GAPDH (Millipore) 
12. Secondary antibodies 
a. Goat anti-mouse 800 (LiCor Biotechnology): use at 1:15,000 dilution. 
b. Goat anti-mouse 680 (LiCor Biotechnology): use at 1:15,000 dilution. 
13. Rac1 activation assay kit (Cytoskeleton). The kit contains lysis buffer and PAK-GST 
glutathione sepharose beads. Reconstitute beads in 500 µL of sterile distilled water to 
yield a stock concentration of 1 mg/mL. Store 20-µL aliquots at -80°C.  
14. RhoA activation assay kit (Cytoskeleton). The kit contains lysis buffer and Rhotekin-
GST glutathione sepharose beads. Reconstitute beads in 500 µL of sterile distilled 
water to yield a stock concentration of 1 mg/mL. Store 20-µL aliquots at -80°C. 
15. Standard equipment, reagents and buffers for SDS-polyacrylamide gel 
electrophoresis (PAGE) and Western blot. For signal detection we favor a 
fluorescence-based system 
 
3. Methods 
 
3.1 Platelet Isolation 
 
3.1.1 Human platelet isolation 
 
1. Using standard venipuncture techniques collect whole blood from the vein of a healthy 
volunteer into a syringe containing ACD to achieve a ratio of 1:5 (ACD:blood). Mix the 
syringe gently to ensure ACD is fully mixed with the blood (see Note 7). 
 
2. Transfer the blood from syringe to 10-mL bijou tubes.  
 
3. Centrifuge the bijou tubes at 180×g for 10 min at room temperature.  
 
4. Transfer the top two thirds of the platelet rich plasma (PRP) into separate bijou tubes.  
 
5. The tubes containing the whole blood are then re-centrifuged at 200×g for additional 
10 min at room temperature.  
 
6. The remaining PRP is then removed, trying not to disturb the buffy coat. This PRP is 
then combined with the PRP collected in step 4.  
 
7. Adjust the pH of the collected PRP to 6.4 by adding 20 µL/mL of 0.3 M citric acid. This 
PRP is then centrifuged at 650×g for 12 min at room temperature.  
 
8. The supernatant containing the platelet poor plasma (PPP) is discarded. Resuspend 
the platelet pellet gently in 3 mL of wash buffer (see Note 8). 
 
9. Centrifuge the re-suspended pellets for additional 12 min at 1000×g at room 
temperature. 
 
10. Drain the supernatant and wipe the inside of the tube using a tissue. Care must be 
taken to not to disturb the pellet.  
 
11. Resuspend the pellet in modified Tyrode’s buffer.  
 
12. Platelets are then incubated for 30 min at 37°C to rest before use.  
 
13. During platelet resting obtain a platelet count using either a Beckman Coulter counter 
or a hemocytometer (see Note 9). 
 
3.1.2 Mouse platelet isolation 
 
1. Euthanize mouse according to appropriate ethical guidelines (see Note 10). Using 
scissors open the abdominal wall and gently push the intestines to your right hand 
side to expose the inferior vena cava (see Note 11). 
 
2. Take blood from the inferior vena cava into a 1-mL syringe with a 25G needle 
containing 50 µL of ACD. 
 
3. Remove the needle and transfer blood into a microcentrifuge tube containing 200 µL 
of Tyrode’s buffer. 
 
4. Centrifuge blood at 400×g for 6 min in a microcentrifuge. 
 
5. Remove the top 700 µL of blood from the tube. 
 
6. Centrifuge the blood at 200×g for 6 min in a swingout centrifuge. 
 
7. Remove the PRP from the blood (see Note 12) and transfer to a fresh tube. 
 
8. If needed add 200 µL of Tyrode’s buffer to the blood and repeat steps 6 and 7. 
 
9. Add either 1 µL of 2 mM PGI2 or 20 µL of 0.3 M citric acid to the PRP and centrifuge 
at 1000×g for 6 min in a swingout centrifuge. 
 
10. Remove the plasma, resuspend the platelets in Tyrode’s buffer and count using either 
a Beckman Coulter counter or a hemocytometer. 
3.2 Platelet Spreading for Imaging Analysis (Fixed) 
 
1. Place 12-mm glass coverslips into the relevant number of wells in a 24-well plate. 
 
2. Coat the coverslips by pipetting up to 200 µL of the matrix protein of choice onto the 
coverslips within the wells. Prepare a BSA-only control at this point (have one 
coverslip to which PBS-BSA is added). The matrix protein will be held in place by 
surface tension on the coverslip and so will not cover the whole of the well. Cover the 
24-well plate with the lid and incubate at 4oC overnight (see Note 13). 
 
3. On the day of use prepare a minimum of 500 mL of PBS for washing coverslips and 
turn on incubator and set to 37oC. 
 
4. Remove the plates from the fridge and remove the matrix protein solution. Then wash 
the coverslips twice with 500 µL of PBS to remove any unbound matrix protein using 
a Pasteur pipette or an aspiration device. Leave the plates covered with PBS. 
 
5. Block the coverslips with 300 µL of PBS-BSA for 1 h at room temperature.  
 
6. Remove the PBS-BSA solution and then wash the coverslips twice with 500 µL of 
PBS to remove any unbound BSA using a Pasteur pipette or aspiration device.  
 
7. At this point resuspend washed platelets to 2×107/mL in Tyrode’s buffer. There are 
now two different methods that can be followed.  
3.2.1. Prior incubation of inhibitors method 
1. Add Rho GTPase inhibitors to the platelet suspension at the correct concentration 
(see Subheading 2.2 item 9). Preincubate the inhibitors with the platelets for 2 min 
prior to addition to the coverslips. 
 
2. Pipette 200 μL of platelet suspension onto each coverslip.  Place the lid on the 24-
well plate, and then place the 24-well plate in the 37oC incubator for 45 min to allow 
platelets to adhere to the coverslips. 
 
3. After 45 min take out the plate from the incubator and remove the solution. Wash the 
coverslips twice with 500 µL of PBS to remove any unbound platelets using a Pasteur 
pipette or aspiration device.   
 
4. After washing place the 24-well plate in a fume hood and add 300 µL of fixing solution 
onto each of the coverslips and leave for 10 min at room temperature to fix the 
adhered platelets.    
 
5. After 10 min, still in the fume cupboard, remove the fixing solution and wash the 
coverslips twice with 500 µL of PBS to remove any excess paraformaldehyde using a 
Pasteur pipette or aspiration device (see Note 14). 
 
6. To permeabilize the platelet cell membrane, remove the PBS and pipette 200 μL of 
permeabilizing solution onto the wells and incubate for 5 min at room temperature. 
 
7. Remove the permeabilizing solution with a Pasteur pipette or aspiration device and 
then wash coverslips twice with 500 µL of PBS to remove any excess Triton X-100. 
 
8. If only staining of the actin cytoskeleton is needed proceed to step 10. Otherwise, to 
complete antibody staining prepare the correct antibody mix and concentration in 
PBS.  Then remove the PBS and add 200 µL of antibody mix to each coverslip for the 
appropriate incubation time (see Note 15).  
 
9. Remove the antibody mix from the coverslips and then wash twice with 500 µL of 
PBS with a Pasteur pipette.   
 
10. To identify the actin cytoskeleton a phalloidin staining can be performed: prepare a 
1:1000 dilution of FITC or TRITC-phalloidin in PBS.  Otherwise to complete the 
antibody staining alongside staining for the actin cytoskeleton, remove the PBS of the 
last wash step. Prepare a 1:1000 dilution of FITC or TRITC-phalloidin in PBS and add 
the relevant secondary antibody dilution to identify the presence of your primary 
antibody. Pipette 200 μL of the secondary antibody/phalloidin mix onto each of the 
coverslips. Cover the 24-well plate in tin foil for 30-60 min at room temperature to 
allow staining to take place. (see Note 16). 
 
11. After 30-60 min remove the secondary antibody/phalloidin mix and wash twice with 
500 µL of PBS to remove excess phalloidin.  
 
12. Now the slides are ready to mount. Place the appropriate amount of mounting 
medium (2-3 µL per coverslip) on each coverslip, remove the coverslips from the 24-
well plate with tweezers and place them on glass slides (see Note 17).  Leave the 
slides overnight in the fridge covered in tin foil (see Note 18). 
 
13. Image slides using either a conventional fluorescence or a confocal microscope with 
63× or 100× oil immersion lenses. 
3.2.2. Post treatment of inhibitors spreading method 
This method allows the platelets to spread for a period of time before addition of the 
inhibitors.  
1. Pipette 200 μL of platelet suspension onto each coverslip.  Place the lid on the 24-
well plate, and then place the 24-well plate in the 37oC incubator for 25 min to allow 
platelets to adhere to the coverslips (see Note 19).  
2. After 25 min take out the plate from the incubator and remove the solution. Then wash 
the slides twice with 500 µL of PBS to remove any unbound platelets using a Pasteur 
pipette.  
3. At this point add solutions of the relevant inhibitors (see Subheading 2.2 item 9) made 
up in Tyrode’s buffer to the coverslips and then place back in the incubator for 10-60 
min. 
4. After the relevant period of time remove the inhibitor solutions and wash twice with 
500 µL of PBS to remove any excess inhibitors. 
5. Fix and stain as per the prior incubation method (from step 4 of Subheading 3.2.1). 
3.2.3. Image analysis 
To complete the relevant image analysis Image J is used. If Zeiss, Zen software is used to 
take the images, then the .czi files can be imported into ImageJ using the Bioformats plugin 
(see Note 20).  The Bioformats plugin can read the .czi files, and will identify the relevant 
sizing information in the image. However if JPEG or TIFF files are imported it will be 
necessary to have the correct sizing information to put into image J. In this case a graticule 
image will be require to identify how many pixels in the image correspond to a certain 
distance. 
1. Adhesion analysis. 
a. Take 5 random fields of view. 
b. Count all the platelets present in the field of view.  However these must be complete 
platelets.  If you are only able to see half a platelet this does not count in the adhesion 
count. 
c. The graph can then be standardized either to the control, or can be presented as the 
number of platelets per a defined area. 
2. Spreading analysis. 
a. Take 100 random platelets from across 5 fields of view. 
b. Use the free draw tab on ImageJ to draw individually around each platelet.  Then 
measure the area (Ctrl+m). 
c. Average the 100 measurements 
3. Stress fiber and actin nodule analysis. 
a. Take 5 random fields of view. 
b. Identify if a platelet contains actin nodules (see Figure 1) or stress fibers (see Figure 1). 
Some platelets may contain both.   
c. The number of platelets containing either stress fibers or actin nodules is then divided 
by the number of platelets on that field of view to obtain a percentage. This is 
completed for all 5 fields of view. 
4. Actin nodule analysis. 
a. Take 5 random fields of view. 
b. Identify if a platelet contains actin nodules (see Figure 1). 
c. Count the number of actin nodules within each platelet. 
d. Actin nodule size is determined through the circling of punctate areas of dense actin 
staining, previously identified as actin nodules, using ImageJ and the Bioformats plugin. 
100 actin nodules in total are analyzed in actin nodule-positive, stress fiber-negative 
platelets and their size averaged.  
All of these analyses will be completed on three separate experiments in order to be able to 
identify statistical significance. 
3.3 Platelet Spreading for Imaging Analysis (Real time) 
1. Prepare 24-well or 6-well glass bottomed dishes with the relevant matrix protein as 
per Subheading 3.2. 
2. Resuspend washed platelets to 2×107/mL in Tyrode’s buffer. Add 500 µL or 2 mL of 
platelet suspension to each well of the 24-well or 6-well dishes respectively.   
3. Monitor spreading using either DIC or fluorescence (if platelets express a fluorescent 
protein) microscopy for up to 1 h at 37°C. 
4. Spread platelets can then be fixed, stained and imaged as per Subheading 3.2.1, 
from step 4. 
3.4 Platelet Spreading for Western Blotting and Pulldown Analysis 
The following protocol describes the preparation of lysates from spread platelets for western 
blotting or to determine the levels of activated Rho GTPases using pulldown assays. The 
procedure can be carried out in 6-well plates for western blotting or in 10-cm dishes for 
GTPase activation assays. Prepare the required number of wells or dishes depending on the 
experimental conditions and time points and the corresponding controls. 
3.4.1 Western blotting 
 
1. Coat 6-well plates by pipetting up to 1 mL of the matrix protein of choice onto the 
relevant well. Cover the 6-well plate with the lid and incubate at 4oC overnight (See 
Note 13). 
 
2. On the day of use prepare a minimum of 500 mL of PBS for washing and turn on 
incubator and set to 37oC. 
 
3. Remove the plates from the fridge, remove the matrix protein and wash twice with 1 
mL of PBS to remove any unbound matrix protein. This can be done using a Pasteur 
pipette or aspiration device.     
 
4. Prepare PBS-BSA and block the plates with 1 mL for 1 h at room temperature. 
 
5. Remove the PBS-BSA solution and wash the plates twice with 1 mL of PBS to 
remove any unbound BSA using a Pasteur pipette or aspiration device.  
 
6. At this point resuspend washed platelets to 2×108/mL in Tyrode’s buffer. As per fixed 
spreading, two different methods for platelet spreading can be followed.  
 
7. Prior incubation method:  
 
a. Add Rho GTPase inhibitors to the platelet suspension at the correct 
concentration (see Subheading 2.2 item 9). Preincubate the inhibitors with the 
platelets for 2 min prior to addition to the wells. 
b. Pipette 1 mL of platelet suspension onto each well.  Place the lid on the 6-well 
plate, and then place the 24-well plate in the 37oC incubator for 45 min to 
allow platelets to adhere to the coverslips. 
c. After 45 min take out the plate from the incubator and remove the solution. 
Proceed with step 9. 
 
8. Post-spreading method: 
a. Pipette 1 mL of platelet suspension onto each well.  Place the lid on the 6-well 
plate, and then place the plate in the 37oC incubator for 25 min to allow 
platelets to adhere to the wells (see Note 19).  
b. After 25 min take out the plate from the incubator and remove the solution. 
Then wash the wells twice with PBS to remove any unbound platelets using a 
Pasteur pipette or aspiration device.  
c. At this point add solutions of the relevant inhibitors (see Subheading 2.2 item 
9) made up in Tyrode’s buffer to the wells and then place back in the incubator 
for 10-60 min. 
d. After the relevant period of time remove the inhibitor solutions and proceed 
with step 9. 
 
9. Wash the wells with PBS. Place the plate on ice and add 100 µL of lysis buffer. Use a 
cell scraper is used to ensure that all the platelets are removed from the surface of the 
well.  
 
10. Transfer lysates to microcentrifuge tubes and either freeze down and store at -20°C 
until needed or carry out a protein concentration. 
 
11. Combine equal amounts of protein form the different conditions with 6× Laemmli 
buffer and boil for 5 min. 
 
12. Resolve samples by SDS-PAGE (10% gel) followed by Western blotting using 
standard techniques. Use RhoA and Rac1 specific antibodies to visualize total levels, 
phosphor-specific antibodies to monitor changes in the phosphorylation status and 
GAPDH as a loading control. 
 
13. Image the blots using a fluorescence-based system to ensure linearity of the signals. 
As an example of this method Figure 2 shows the effect of PGI2 on the phosphorylation of 
RhoA. Figure 2a-d shows that RhoASer188 phosphorylation is elevated in the presence of PGI2 
over basal, alongside confirmation of PKA activity via phosphorylation of VASP.  The 
downstream marker of myosin light chain phosphorylation can then also be monitored to 
show the effect of the phosphorylation of RhoA. These effects driven by PGI2 can then be 
reversed in the presence of PKA inhibitors.  These changes in phosphorylation levels can 
then be quantified using densitometry comparing their levels to the loading control GAPDH. 
The phosphorylation of RhoASer188 is thought to correlate to decreased activity levels for the 
Rho GTPases (23). 
3.4.2. Rho GTPase pulldowns 
1. Using 10-cm plates, proceed as in Subheading 3.4.1. steps 1-9 (depending on the 
method) but using 3-mL volumes per plate. 
 
2. At the relevant time point place the plates on ice and wash twice with PBS. 
 
3. Lyse with the RhoA/Rac lysis buffer supplied in the RhoA/Rac pulldown kit (200 µL 
per plate) on ice. Use a cell scraper to ensure that all the platelets are removed from 
the surface of the plate. Transfer the lysates to microcentrifuge tubes. 
 
4. From each individual lysate, 50 µL is used for protein determination and for Western 
blotting for total RhoA/Rac1 protein (see Note 21).  
 
5. Mix 200-300 µg of protein of the lysate with 50 µg of Rhotekin-RBD-beads or PAK-
GST beads and incubate for 90 min on a rotator at 4°C (see Note 22). 
 
6. Pellet the beads by centrifugation at maximum speed in a microcentrifuge for 1 min 
and remove 90% of the supernatant. 
 
7. Wash bead pellets with 400 µL of wash buffer. Ensure the beads are fully 
resuspended in wash buffer (see Note 23). 
 
8. Pellet the beads by centrifugation at maximum speed in a microcentrifuge for 1 min. 
 
9. Remove the supernatant, add 40 µL of 2× Laemmli buffer and boil for 5 min. 
 
10. Resolve total lysate and active samples by SDS-PAGE (10% gel) followed by 
Western blotting using standard techniques. Use anti RhoA or Rac1 primary 
antibodies followed by the appropriate secondary antibodies. 
 
11. Image the blots using a fluorescence-based system to ensure linearity of the signals. 
Densitometries for the active and total RhoA/Rac1 are measured by drawing equal 
sized rectangles to the bands on the blots obtained. These values are converted into 
ratios by dividing the respective active RhoA/Rac1 to its total RhoA/Rac1 counterpart. 
 
As an example of this method Figure 2e,f shows the effect of PGI2 on the activity of RhoA. 
RhoA activity is elevated in control spread platelets.  This elevation is reduced in the 
presence of PGI2 and is then returned normal levels in the presence of PKA inhibitors (Figure 
2e). The fold change can be identified as the band density of the active RhoA compared to 
the band density of the total RhoA (Figure 2f). 
 
4. Notes 
 
1. OxLDL and nLDL are produced within house following published protocols (24-27).    
2. Thrombin is bought from Sigma as a lyophilized powder.  It is then reconstituted as 
per the manufacturer’s instructions to a concentration of 10 U/mL.  This is then 
aliquoted in 10-µL aliquots and stored frozen at -20°C.  Once it is thawed it is used on 
the day and then discarded. 
3. Prostacyclin is diluted in methanol as a 2 mM solution.  It is then stored as 2-µL 
aliquots at -20°C.  If required it is taken out of the freezer just before it is needed as it 
has a half life of 2 min.  Once used it is then discarded. 
4. Indomethacin stock is dissolved in DMSO at a concentration of 10 mM.  It is then 
aliquoted in 5-µL aliquots. DMSO can be used in platelet spreading up to a 
concentration of 0.1%. 
5. The denaturation process ensures that the platelets do not respond to the BSA.  
Therefore a BSA alone slide should have very little platelet adhesion and spreading.  
In addition the BSA can then be used to block the areas of the slide that are not 
covered by the extracellular matrix proteins that has been used. 
6. Phalloidin is very toxic, may be fatal if swallowed, inhaled or absorbed through the 
skin. For personal protection, wear glasses and gloves. Avoid dispersal of material in 
the air or on working surfaces. 
7. Ensure you have the appropriate permissions to withdraw and handle human blood 
according to your institutional guidelines and comply with health and safety 
requirements. 
8. When suspending the pellet ensure that you pipette gently.  The platelets should puff 
off the pellet.  If you disturb large lumps of the pellet, you risk pre-activating the 
platelets as you resuspend them. 
9. When using the Beckman Coulter counter dilute 2.5 µL of platelet suspension in 10 
mL of diluent, and then count.  This will help to ensure that the machine is less likely 
to be blocked by excessive numbers of platelets.  
10. Do not euthanize mice using cervical dislocation, as this will result in tissue factor 
release and activation of the coagulation system preventing removal of blood and 
isolation of platelets. We normally use suffocation by CO2. 
11. Blood can also be collected by cardiac puncture, depending on the preferences and 
skills of the researcher. A good bleeding would yield up to 1 mL of blood from a single 
adult mouse. 
12. When removing the PRP cut off the end of a 200-µL pipette tip, and then take up as 
much of the PRP as possible including the buffy coat.  However try to ensure that you 
do not take up red blood cells. 
13. To ensure the wells stay wet, place a wet towel in the 6/24-well plate to provide a 
humid environment.  
14. At this point the slides can be placed into the fridge and stored for up to a week, 
before staining.  However, staining is best if completed straight away. 
15. The length of time required to complete staining is antibody specific. For many 
antibodies 1 h at room temperature should be sufficient. However, it is sometimes 
necessary to incubate the primary antibody overnight at 4°C to obtain good staining.  
16. The concentration and incubation time of the secondary antibody may also need 
optimizing. Too much or too long incubation of the secondary can lead to non-specific 
binding and high background staining. 
17. When lifting out the coverslip use a 200-µL pipette tip to help lift the coverslip up 
before picking it up with some tweezers.  Ensure that care is taken, as it is easy to 
both break the coverslip and to drop it. 
18. The slides can be left for up to 1 week if required.  However it is always best to image 
the following day to maximize the quality of the fluorescence. 
19. 25 min of spreading has been shown to allow a good number of platelets to adhere, 
and to have the vast majority of those platelets to be fully spread.  This ensures that 
the experiment will be conducted on fully activated platelets.  However longer time 
points can be chosen if required. 
20. The Bioformats plugin can be downloaded from https://imagej.net/Bio-Formats. It can 
then be installed depending on the computer system used. 
21. We use the protein determination kit from Cytoskeleton. It requires only 3 µL of 
sample and can be read after 1 min of incubation.  This improves the speed of the 
experiment, which is critical as Rho GTPases in their active form can easily 
breakdown into their inactive GDP-bound form. 
22. If the protein concentration is too high, then there will be non-specific binding of Rho-
GDP or Rac-GDP to the beads. 
23. Do not invert or flick the microcentrifuge tube, and ensure also that the bead 
suspension is not aspirated into the pipette tip. 
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 Figure legends 
 
Figure 1: Representative images of filopodia, lamellipodia, actin nodule, and stress 
fiber formation in platelets. Platelets (2×107/mL) were incubated for 45 min on coverslips 
coated with 100 µg/mL fibrinogen before fixation, staining with FITC-phalloidin, mounting, and 
imaging with a fluorescent microscope. Images are representative of (a) filopodia formation 
(red arrows) and actin nodules (yellow arrows); (b) lamellipodia formation (blue arrows); (c) 
stress fibers (green arrows). 
 
Figure 2: PGI2 induces a PKA signaling response in spread platelets. (a) Platelets 
(2×108/mL) were spread on 100 μg/mL fibrinogen for 25 min in the presence or absence of 
PKA inhibitors 100 μM RP-8CPT-cAMP (RP) and 2 μM KT5720 (KT), before being washed 
with PBS. The platelets were then treated with Tyrode’s buffer containing 10 nM PGI2 with or 
without PKA inhibitors (100 μM RP-8CPT-cAMP and 2 μM KT5720), or 1 μM forskolin, or 
10 μM Y27632, for a further 10 min. The samples were then lysed with Laemmli buffer before 
being western blotted for pVASPSer159, pMLCSer19, pRhoASer188, and GAPDH. Cropped gel 
Images are representative of at least three experiments. (b–d) Densitometry for the western 
blots; pVASPser159, pMLCser19 and pRhoAser188 using GAPDH as the loading control. The ratios 
were standardized to the control. (e) Spread platelets as in (a) were treated with Tyrode’s 
buffer containing 10 nM PGI2 with or without PKA inhibitors 100 μM RP-8CPT-cAMP and 
2 μM KT5720 for a further 10 min. The samples were then lysed before the addition of 
Rhotekin-GST beads. Samples were then western blotted for active RhoA and total RhoA. 
Cropped gel Images are representative of at least three experiments. (f) Images of RhoA pull 
down were analyzed for densitometry. Analysis is an average of at least n = 3 experiments. 
*p < 0.05 (ANOVA). Reproduced from ref. 13. 
 
